254 results on '"Brandsma, D."'
Search Results
2. Optimizing treatment of brain metastases in an era of novel systemic treatments: a single center consecutive series
3. Leptomeningeal metastasis from solid tumours: EANO–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
4. P2.10-07 ORA-LM: Molecular Analysis in Cerebrospinal Fluid of ALK or EGFR Positive NSCLC Patients with Leptomeningeal Metastases
5. Susac’s syndrome as an immune-related adverse event after pembrolizumab: a case report
6. Optimizing treatment of brain metastases in an era of novel systemic treatments: a single center consecutive series
7. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours
8. Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma
9. Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)
10. OS03.6.A Rituximab in primary CNS lymphoma - long term follow-up of the phase III HOVON 105/ALLG NHL 24 Study
11. P11.61.B Capecitabine treatment of CNS metastases from breast cancer: intracranial response and survival
12. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin
13. Strategies to target drugs to gliomas and CNS metastases of solid tumors
14. P1176: RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY
15. Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity
16. OR189 - ANALYSIS OF OUTCOMES OF TEMPOROMANDIBULAR JOINT NEEDLE ARTHROCENTESIS AND DIAGNOSTIC ARTHROSCOPY WITH INTRAARTICULAR MORPHINE INJECTION
17. Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1
18. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin
19. Symptomatic brain metastases from small-cell carcinoma of the urinary bladder: The Netherlands Cancer Institute experience and literature review
20. P14.40 Trends in distribution of glioblastoma care and patient’s travel distance; results from the Dutch Brain Tumor Registry
21. P14.31 Between hospital variation in timings to multidisciplinary glioblastoma care in the Dutch Brain Tumor Registry
22. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings
23. Inhibition of Cortical Laser-Evoked Potentials by Transcutaneous Electrical Nerve Stimulation
24. Successful management of brain metastasis from malignant germ cell tumours with standard induction chemotherapy
25. Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab
26. Management of meningeal solitary fibrous tumors/hemangiopericytoma; surgery alone or surgery plus postoperative radiotherapy?
27. 372MO Melanoma leptomeningeal metastases: A European multicenter cohort
28. Brain metastases in patients with pelvic or abdominal malignancy do not prevail in the posterior fossa: a retrospective study
29. Susac’s syndrome as an immune-related adverse event after pembrolizumab: a case report
30. Prognostic role of the EANO ESMO classification of leptomeningeal metastases
31. Bevacizumab bij symptomatische cerebrale radiatienecrose
32. IMPROVING QUALITY OF CARE OF MENINGIOMA PATIENTS: INITIAL EVALUATION OF ISSUES IN CARE TRAJECTORIES ACCORDING TO THE PLAN-DO-STUDY-ACT CYCLE
33. Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study
34. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma
35. Primary CNS lymphoma in HIV infection
36. Leptomeningeal metastases of a well-differentiated neuroendocrine tumour: a rare entity
37. Management of meningeal solitary fibrous tumors/hemangiopericytoma; surgery alone or surgery plus postoperative radiotherapy?
38. P05.78 Improving quality of care of meningioma patients: initial evaluation of issues in care trajectories according to the Plan-Do-Study-Act Cycle
39. 391O - Prognostic role of the EANO ESMO classification of leptomeningeal metastases
40. Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy
41. Necrotizing myopathy, an ocular myasthenic syndrome and subclinical myocarditis associated with pembrolizumab treatment for metastatic melanoma
42. Neurological benefit of BRAF-inhibition and MEK-inhibition in patients with brain metastases from BRAF-mutated melanoma
43. PHASE 1/2A STUDY OF GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN (2B3-101) IN BREAST CANCER PATIENTS WITH BRAIN METASTASES (BCBM) OR RECURRENT HIGH GRADE GLIOMAS (HGG)
44. 2B3-101, GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS AND BREAST CANCER BRAIN METASTASES
45. Outcome of patients with primary central nervous system lymphoma treated outside clinical trials
46. P13.09 Survival and relapse of brain metastases after complete resection of a single brain metastasis without postoperative whole brain radiotherapy - a retrospective study
47. OC-0160: Growth and oedema related shifts of brain metastasis treated with stereotactic radiosurgery
48. Survival of breast cancer patients with synchronous or metachronous central nervous system metastases
49. Strategies to target drugs to gliomas and CNS metastases of solid tumors
50. Provider perceptions of clinical neuropathy examination usefulness
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.